Eiger BioPharmaceuticals shares are trading higher after Baird raised its price target on the stock from $3 to $5. The company on Thursday announced a reorganization and portfolio prioritization.
Portfolio Pulse from Benzinga Newsdesk
Eiger BioPharmaceuticals' stock price is trading higher following Baird's decision to raise its price target from $3 to $5. This comes after the company announced a reorganization and portfolio prioritization.
June 30, 2023 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eiger BioPharmaceuticals' stock price is expected to rise in the short term due to Baird's raised price target and the company's recent reorganization and portfolio prioritization.
Baird's raised price target indicates a positive outlook for Eiger BioPharmaceuticals, which is likely to attract investors and drive up the stock price. Additionally, the company's reorganization and portfolio prioritization could be seen as a strategic move to enhance its operations and profitability, which could further boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100